Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

0.7301
-0.0062-0.84%
Post-market: 0.7300-0.0001-0.01%18:33 EDT
Volume:109.23K
Turnover:80.59K
Market Cap:14.36M
PE:-0.94
High:0.7713
Open:0.7413
Low:0.7200
Close:0.7363
52wk High:3.78
52wk Low:0.6900
Shares:19.67M
Float Shares:17.33M
Volume Ratio:0.55
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7779
EPS(LYR):-1.1986
ROE:-2543.13%
ROA:-39.29%
PB:-25.60
PE(LYR):-0.61

Loading ...

VistaGen Q1 Revenue Rises on Licensing Agreement Expiration

Reuters
·
Aug 14

Dare Bioscience Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Dare Bioscience, Inc. Q2 EPS USD -0.2

THOMSON REUTERS
·
Aug 14

Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate

Benzinga Earnings
·
Aug 14

Daré Bioscience Q2 FY26 Net Loss Narrows to $2.98 Million; Revenue Rises to $187,546

Reuters
·
Aug 14

DarÉ Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

THOMSON REUTERS
·
Aug 14

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

GlobeNewswire
·
Aug 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

Dare Bioscience Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Daré Bioscience to Host Quarterly Results Conference Call and Webcast

Reuters
·
Aug 06

DarÉ Bioscience Expands Access Options for Dare to Play™ and Specialized Menopause Care Through Strategic Collaboration with Mymenopauserx

THOMSON REUTERS
·
Jul 28

Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

GlobeNewswire
·
Jul 28

Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic?

Simply Wall St.
·
Jul 21

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

GlobeNewswire
·
Jul 20

Daré Bioscience Advances DARE-HPV Trial, Raising New Questions for HPV Treatment Investors

TIPRANKS
·
Jul 18

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

GlobeNewswire
·
Jul 09

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

GlobeNewswire
·
Jul 01

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

GlobeNewswire
·
Jun 25

Daré Bioscience CEO speaks at BIO International Convention 2026

Reuters
·
Jun 18

Daré Bioscience shareholders approve 1.5 million-share increase to 2022 stock incentive plan at annual meeting

Reuters
·
Jun 13